CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. reported a strong turnaround for the quarter ended June 30, 2026. Revenue reached $132 million, up 52% year-over-year, led by testing services revenue of $100 million on 17% higher volume and richer reimbursement, including $16 million of prior-period revenue. Patient and digital solutions contributed $19 million and lab products $13 million. Net income was $111 million, compared with a $9 million loss a year earlier.
The company closed the sale of its lab products business, receiving approximately $171.7 million and recognizing a gain of about $113.0 million, which also drove operating cash flow of $31 million and period-end cash, cash equivalents and restricted cash of $374,157 thousand. Subsequent to quarter end, CareDx acquired Naveris for $161.8 million in cash plus up to $100.0 million in earn-outs, expanding its specialty oncology footprint. Key risks include heavy reliance on Medicare, which represented about 30% of revenue, and ongoing patent litigation with potential exposure of up to $96.3 million plus interest.
CareDx, Inc. reported strong second quarter 2026 results, with revenue of $132 million, up 52% year-over-year, driven mainly by Testing Services. Testing Services revenue was $100 million, an increase of 61% year-over-year on approximately 58,000 tests, up 17%. Patient and Digital Solutions revenue reached $19 million and Lab Product revenue was $13 million, growing 50% and 8% year-over-year, respectively.
CareDx generated GAAP net income of $111 million versus a GAAP net loss of $9 million a year earlier, including a $113 million gain on the sale of its Lab Products business. Non-GAAP net income was $20 million compared to $6 million, and adjusted EBITDA was $25 million versus $5 million, with non-GAAP gross margin at 74%. Cash flow from operations was $31 million, and free cash flow was $28.7 million.
The company completed the divestiture of its Lab Products business to Eurobio Scientific and closed the acquisition of Naveris, sharpening its focus on transplant, specialty oncology, and cell therapy. It raised 2026 revenue guidance to $490–$500 million and adjusted EBITDA guidance to $66–$78 million. Recent milestones include finalized Medicare coverage for AlloSure and AlloMap and multiple clinical data presentations across its AlloHeme, HistoMap Kidney, NavDx, and AlloSure Kidney programs.
BlackRock, Inc. filed an amended Schedule 13G (Amendment No. 8) reporting its beneficial ownership of common stock of CareDx, Inc.. BlackRock reports beneficial ownership of 4,664,092 shares of CareDx common stock, representing 9.0% of the outstanding class.
BlackRock reports sole voting power4,575,539 shares and sole dispositive power4,664,092 shares, with no shared voting or dispositive power. The filing explains that the reported holdings reflect securities beneficially owned, or deemed to be beneficially owned, by certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, but no individual person has an interest exceeding five percent of the total outstanding common shares.
CareDx, Inc. director and President & CEO Hanna John Walter JR reported option exercises and share sales dated July 16, 2026. He exercised 118,000 employee stock options at $8.2000 per share, acquiring common stock, and sold 118,000 shares in sales at weighted average prices of $36.1141 and $39.0137, effected pursuant to a Rule 10b5-1 trading plan adopted December 12, 2025. Following these transactions, he reported direct ownership of 653,448 common shares and 512,706 employee stock options.
CareDx, Inc. director Hannah Valantine reported multiple equity transactions in Common Stock on July 16, 2026. She sold a total of 28,779 shares, including 28,679 shares at a weighted average price of $36.1445 (individual trades from $35.55 to $36.50) and 100 shares at $36.55, under a Rule 10b5-1 trading plan adopted on December 11, 2025. She also exercised fully vested stock options for 28,779 shares at exercise prices of $7.96, $14.19 and $20.56 per share. Following the reported transactions, she held 36,786 shares of CareDx Common Stock directly.
CDNA shareholder John Hanna filed a notice indicating plans to sell 118,000 shares of common stock on or about 07/16/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $3,510,500.00. Shares outstanding were 51,659,481 as reported by the issuer; this is a baseline figure, not the amount being sold.
The shares to be sold are tied to an Exercise of Stock Options for cash. Over the prior three months, Hanna reported several "10b5-1 Sales" of common shares, including 39,900 shares for $1,166,835.60 on 06/29/2026 and 21,998 shares for $528,441.55 on 06/11/2026.
CDNA stockholder Hannah Valantine has filed a Form 144 notice covering the proposed sale of 28,779 shares of common stock, associated with a value of $856,175.25, to be sold through Morgan Stanley Smith Barney on NASDAQ on or after 07/16/2026. The shares are linked to an Exercise of Stock Options. Over the prior three months, she sold 12,103 common shares on 06/15/2026, described as 10b5-1 Sales, with a stated value of $279,728.17.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported an automatic equity grant and updated holdings. He received a grant of 1,746 shares of Common Stock at $0.00 per share as quarterly non-employee director compensation in lieu of cash under the company’s Outside Director Compensation Policy.
Following this grant, Goldberg holds 106,438 Common Stock shares directly. A separate entry shows 91,045 Common Stock shares held indirectly by the Cavallo Trust, for which Goldberg and his spouse serve as trustees. The filing reflects routine compensation and ownership reporting rather than open-market buying or selling.
CareDx, Inc. completed two major portfolio moves. It sold its Swedish CareDx AB subsidiary and kitted lab products and software business to Eurobio Scientific for an aggregate $171.7 million in cash, sharpening focus on U.S. precision medicine testing and digital solutions.
The company also closed its acquisition of Naveris, Inc. for $161.8 million in cash plus up to $100.0 million in revenue-based milestone payments. Naveris’ NavDx test is Medicare-covered at $1,800 and generated about $35 million of revenue in 2025, helping expand CareDx’s estimated addressable market to over $12 billion across transplant, specialty oncology, and cell therapy.